Holen Sie sich die Stockscreener-App
3.75
3.59%
0.13
Schlusskurs vom Vortag:
$3.62
Offen:
$3.63
24-Stunden-Volumen:
1.76M
Relative Volume:
2.37
Marktkapitalisierung:
$355.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.43M
KGV:
-3.0735
EPS:
-1.2201
Netto-Cashflow:
$-72.75M
1W Leistung:
+4.75%
1M Leistung:
-8.98%
6M Leistung:
-12.18%
1J Leistung:
+237.84%
1-Tages-Spanne:
$3.52
$3.795
1-Wochen-Bereich:
$3.51
$3.855
52-Wochen-Spanne:
$1.00
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
3.75 | 355.80M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Wedbush | Outperform |
| 2024-11-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-05-03 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Guggenheim | Buy |
| 2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes - Stock Titan
Zura Bio Ltd (ZURA) Institutional Confidence - TradingKey
Zura Bio Stockanalyst focus on early-stage pipeline - AD HOC NEWS
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd stock (KYG989201089): Pipeline update and capital raise reshape the story - AD HOC NEWS
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Zura Bio's new CBO gets options on 600,000 shares at $4.80 - Stock Titan
Zura Bio appoints Muzammil Mustufa as chief business officer By Investing.com - Investing.com Canada
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - ChartMill
TradingKey - TradingKey
Suvretta/Averill disclose large ZURA stakes (NASDAQ: ZURA) in 13G/A filing - Stock Titan
Jessica Chen - White & Case LLP
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m - simplywall.st
Zura Bio Ltd 1Q 2026: Net income $(24.2M), EPS $(0.22) — 10-Q Summary - TradingView
Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M - Stock Titan
Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens - Stock Titan
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Zura says it has enough cash to operate through 2028 as two trials advance - Stock Titan
JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio | DEF 14A: Definitive information statements - Moomoo
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio | ARS: Annual Report to Security Holders - Moomoo
[ARS] Zura Bio Ltd SEC Filing - Stock Titan
[DEF 14A] Zura Bio Ltd Definitive Proxy Statement - Stock Titan
ZURA News | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio Limited 8-K Filing Details April 2026 – Separation Agreement, Company Information, and SEC Compliance - Minichart
Zura Bio LtdEric Hyllengren separated from Zura Bio Limited as CFO on April 20, 2026 - marketscreener.com
Zura Bio : Corporate Overview April 2026 (d9fec3) - marketscreener.com
Zura Bio Limited Announces CFO Changes, Effective April 20, 2026 - marketscreener.com
[8-K] Zura Bio Ltd Reports Material Event - Stock Titan
One Zura Bio Insider Raised Their Stake In The Previous Year - Yahoo Finance
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering - Benzinga
JATT Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
JATT Technical Analysis & Stock Price Forecast - Intellectia AI
JATT PE Ratio & Valuation, Is JATT Overvalued - Intellectia AI
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):